

Special Issue

Design and Development of New Anticancer Agents with Selectivity for Tumors and Their Metastases

Message from the Guest Editor

The design and development of new anticancer agents with selectivity for tumors and their metastases is a very broad and popular topic in the new approach to medicinal chemistry. The aim of this Special Issue is to provide a wide spectrum of the newest strategies in drug development explored in research teams. First, we want to identify the most popular structures present in many anticancer compounds known as privileged structures. Additionally, we want to collect the most important molecular targets (signaling pathways, proteins involved, receptors, etc.) which are of interest to researchers focused on anticancer therapy.

Guest Editor

Dr. Anna Mrozek-Wilczkiewicz

Chełkowski Institute of Physics, Faculty of Science and Technology,
University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów,
Poland

Deadline for manuscript submissions

closed (31 March 2022)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/57538

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).